Spruce Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
41.9%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$24.89next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly54.1MTarget: Sufficient to fund operations into the second half of 2027
Research and Development (R&D) Expenses Quarterly7.6MTarget: Disciplined spending focused on TA-ERT
Net Loss Quarterly12.3MTarget: Narrowing losses through strategic pivot
Watch Items
- TA-ERT Biologics License Application (BLA) SubmissionTrigger: Submission to the FDAAction: Monitor regulatory interactions and manufacturing readiness for Q4 2026 target.
- TAMARIND Phase 2 Trial of Tildacerfont in MDDTrigger: Discontinuation of trial due to safety eventAction: Monitor the wind-down and any residual liabilities or safety reporting requirements following the trial's discontinuation.
- Confirmatory Study Initiation for TA-ERTTrigger: First patient dosedAction: Verify initiation of the confirmatory trial prior to potential accelerated approval.
Research as of 19 Jun 2026